BioWorld

Nov. 19, 2003

View Archived Issues

Neose, Novo Enter Potential $55.6M Protein License Dea

Diabetic Mice Reveal Insulin In Spleen Cells, Pointing To Human Type I Cure In Pending Clinicals

Focused On Brain, CNS Disorders, Saegis Raises $30M In Its Series B

Phoenix Pharmacologics Starts Phase III Study In Liver Cancer

Keryx Has Cash For Three Years After $15M Private Placement

Vitex Halts Phase III Chronic Trial Of Inactine, Seeks New Financing

Other News To Note

Genome Therapeutics, Genesoft To Merge In $80M All-Stock Deal

Genome Therapeutics Inc. and Genesoft Pharmaceuticals Inc. said they have entered a definitive agreement for an all-stock merger that would leave the new entity with one antibiotic preparing to launch and another in Phase III trials. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...